APA (7th ed.) Citation

MW, L., B, S., M, M., CA, S., KA, J., PB, S., . . . S, R. (2024). Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: Results from a substudy of the ASPIRO open-label clinical trial. EBioMedicine, 99, 104894. https://doi.org/10.1016/j.ebiom.2023.104894

Chicago Style (17th ed.) Citation

MW, Lawlor, et al. "Effects of Gene Replacement Therapy with Resamirigene Bilparvovec (AT132) on Skeletal Muscle Pathology in X-linked Myotubular Myopathy: Results from a Substudy of the ASPIRO Open-label Clinical Trial." EBioMedicine 99 (2024): 104894. https://doi.org/10.1016/j.ebiom.2023.104894.

MLA (9th ed.) Citation

MW, Lawlor, et al. "Effects of Gene Replacement Therapy with Resamirigene Bilparvovec (AT132) on Skeletal Muscle Pathology in X-linked Myotubular Myopathy: Results from a Substudy of the ASPIRO Open-label Clinical Trial." EBioMedicine, vol. 99, 2024, p. 104894, https://doi.org/10.1016/j.ebiom.2023.104894.